Baird downgraded Immutep (IMMP) to Neutral from Outperform with a price target of $1, down from $7. The Independent Data Monitoring Committee recommended the discontinuation of the company’s pivotal TACTI-004 study in non-small cell lung cancer following the study’s planned futility analysis, the analyst tells investors in a research note. The firm is surprised by the result and does not see a clear path forward for efti.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMP:
- Immutep downgraded to Market Perform from Outperform at Citizens
- Immutep Doubles Half-Year Loss as R&D Spend Rises Despite New Dr. Reddy’s Funding
- Immutep initiated with an Outperform at Citizens
- Immutep Reaches 50% Enrolment in Global Phase III Lung Cancer Trial
- Immutep achieves 50% enrollment in global TACTI-004 Phase III trial